Section of Adult Congenital and Adult Heart Disease, Cardiovascular Diagnosis and Endoluminal Interventions, Rovigo General Hospital, Rovigo, Italy.
J Cardiovasc Med (Hagerstown). 2010 Feb;11(2):91-5. doi: 10.2459/JCM.0b013e32832f4046.
Hypertrophy and lipomatosis of the interatrial septum have been thought to be contraindications for transcatheter patent foramen ovale (PFO) and atrial septal defect closure because of the limits of current devices and the risk of suboptimal results. No reports have been produced yet about PFO closure in patients with such conditions. We retrospectively assessed the safety and effectiveness of PFO closure in patients with hypertrophy or lipomatosis of fossa ovalis rims.
We searched our database of 140 consecutive patients (mean age 43 +/- 15. 5 years, 98 female patients) who underwent transcatheter PFO closure for cases of hypertrophy or lipomatosis of the interatrial septum. All patients were screened with transesophageal echocardiography before the operation. All patients underwent intracardiac echocardiography study and attempted closure.
Ten patients (7.1%) underwent an attempt at transcatheter closure in the presence of hypertrophy of the rims (eight patients) or lipomatosis (two patients). All patients were aged more than 50 years and has multiple recurrent stroke events (nine patients) or need for a posterior cerebral surgical procedure (one patient) making closure mandatory. After intracardiac echocardiography study and measurements, two 25 mm Amplatzer and eight 25 mm Premere Occlusion System devices have been implanted successfully. On mean follow-up of 36.6 +/- 14.8 months, two patients had a small residual shunt: no recurrence of stroke or aortic erosion or device thrombosis was observed during this period.
Transcatheter PFO closure in the presence of hypertrophy or lipomatosis of fossa ovalis rims is not contraindicated per se: careful evaluation of rim thickness with intracardiac echocardiography and selection of soft and asymmetrically opening devices may allow for a safe and effective PFO closure, at least in patients with no severe atrial septal aneurysm.
由于现有设备的限制和结果不理想的风险,人们认为房间隔膨胀和脂肪化生是经导管卵圆孔未闭(PFO)和房间隔缺损封堵的禁忌证。目前尚无关于此类病变患者 PFO 封堵的报道。我们回顾性评估了在房间隔膨出缘肥厚或脂肪化生患者中行 PFO 封堵的安全性和有效性。
我们在 140 例连续行经导管 PFO 封堵术的患者数据库中搜索了房间隔膨出缘肥厚或脂肪化生的病例。所有患者在手术前均经食管超声心动图筛查。所有患者均进行了心内超声检查并尝试封堵。
10 例(7.1%)患者在膨出缘肥厚(8 例)或脂肪化生(2 例)的情况下尝试行经导管封堵。所有患者年龄均大于 50 岁,且有多次复发性卒中事件(9 例)或需要进行后颅手术(1 例),故必须进行封堵。心内超声检查和测量后,成功植入 2 个 25mm 的 Amplatzer 和 8 个 25mm 的 Premere Occlusion System 封堵器。平均随访 36.6±14.8 个月,2 例患者有小残余分流:在此期间未观察到卒中复发、主动脉侵蚀或器械血栓形成。
房间隔膨出缘肥厚或脂肪化生本身并非经导管 PFO 封堵的禁忌证:用心内超声仔细评估缘厚度,并选择柔软且不对称开放的封堵器,可能会实现安全有效的 PFO 封堵,至少在无严重房间隔瘤的患者中如此。